Genotype-specific treatment regimens for HCV infection

Genotype-specific regimens for the treatment of people with HCV infection are still listed on the PBS. Elbasvir plus grazoprevir and sofosbuvir plus ledipasvir are genotype-specific treatment regimens, and HCV genotype should be determined before prescribing either of these regimens. Both regimens are well tolerated and have efficacy ≥ 95% in people with no cirrhosis, as well as in people with cirrhosis.

Several other genotype-specific regimens for the treatment of HCV infection are no longer marketed in Australia and have been removed from this consensus statement. These include sofosbuvir plus daclatasvir, with or without ribavirin; sofosbuvir plus ribavirin; and paritaprevir (ritonavir-boosted) plus ombitasvir plus dasabuvir (PrOD), with or without ribavirin.